MIT researchers invent game-changing product that could revolutionize agriculture: 'You could give back a billion dollars to US growers'
Agricultural spraying involves mixing water with chemicals and applying droplets to plant leaves, which are inherently water-repellent, according to a report by MIT News.
After testing a variety of methods to optimize the delivery of pesticides and other sprays, the team ended up coating water droplets with a small amount of oil to help them adhere to the leaves.
"Basically, this oil film acts as a way to trap that droplet on the surface, because oil is very attracted to the surface and sort of holds the water in place," said Simon Rufer, an MIT graduate student and co-author of a study on the topic.
During initial tests, the researchers used soybean oil, figuring that this material would be familiar to farmers, many of whom grow soybeans, the report explained.
However, soybean oil wasn't part of the usual supply chains, so they found that several of the chemicals they were already using could be employed in the same way.
"That way, we're not introducing a new chemical or changed chemistries into their field, but they're using things they've known for a long time," said Kripa Varanasi, an MIT professor involved in the project.
Pesticide use has been steadily increasing across the globe, rising 20% over the last decade, and even up to 153% in low-income countries.
The use of this and other types of sprays across the nearly 1.2 billion acres of agricultural land in the U.S. adds up both in terms of quantity and costs. Approximately half a million tons of pesticides, 12 million tons of nitrogen, and four million tons of phosphorus fertilizer are applied to crops across the country.
By using the new system, which is being commercialized by AgZen, a spinoff company created by the researchers, farmers can reduce the amount of spray they need to use on crops.
Do you worry about pesticides in your food?
All the time
Sometimes
Not really
I only eat organic
Click your choice to see results and speak your mind.
"You could give back a billion dollars to U.S. growers if you just saved 6 percent of their pesticide budget," said Vishnu Jayaprakash, lead author of the research paper and CEO of AgZen. "In the lab we got 300 percent of extra product on the plant. So that means we could get orders of magnitude reductions in the amount of pesticides that farmers are spraying."
This adhesive effect also helps reduce agricultural runoff, a leading cause of water quality degradation in rivers and streams. It also helps reduce soil erosion, nutrient loss, and the spread of pesticides into our waterways.
The system, which AgZen calls RealCoverage, has already been deployed across 920,000 acres of farmland and various crop types, saving farmers up to 50% on their pesticide expenditures, the report explained.
The RealCoverage system requires a nozzle that fits most spraying equipment and provides real-time coverage data using its onboard AI, so that it can be fine-tuned, even while in use.
"The knowledge we are gathering from every leaf, combined with our expertise in interfacial science and fluid mechanics, is giving us unparalleled insights into how chemicals are used and developed — and it's clear that we can deliver value across the entire agrochemical supply chain," Varanasi said, per MIT News.
"Our mission is to use these technologies to deliver improved outcomes and reduced costs for the ag industry."
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Screen Geek
43 minutes ago
- Screen Geek
'Jurassic World: Rebirth' Review: It's Fine And That's Okay
It's been ten years since audiences were reintroduced to the world of dinosaurs with the release of 2015's Jurassic World . Yeah, I feel like that Matt Damon aging gif too. The legacy sequels to 1993's Jurassic Park gave us three movies, whose entertaining quality dropped like a pterosaur nose-diving into the ocean. However, the trilogy generated enough of a box office return that Universal Pictures and Amblin Entertainment gave it another try with Jurassic World: Rebirth . Rebirth is set to be another step in continuing to build the franchise by giving us what we love about dinosaurs in the modern world. The combination of director Gareth Edwards and David Koepp's writing showcases that the franchise still has legs. This somewhat new direction for the series leans further into a Dino Crisis-like setting and might be worth exploring in future films. Jurassic World: Rebirth , directed by Edwards, takes the script by Koepp and adds a more horror and adventure element to the franchise. The story revolves around a group of mercenaries on a mission to reach a research island—formerly owned by InGen—where dinosaurs were previously experimented on. Heading the group is veteran former ex-military covert operative, Zora Bennett (Scarlett Johansson), and paleontologist Dr. Henry Loomis (Jonathan Bailey). Bennett and Loomis are recruited by Martin Krebs (Rupert Friend) of ParkerGenix to travel to the island and gather pure dinosaur biomaterial samples. The hope is that these samples may lead to the development of a medical drug that could potentially bring significant benefits to humanity. Koepp's script hits the ground running with some of its characters in the first Act. The writing cleverly explains how dinosaurs have impacted the world and how the world, in turn, has affected them. It simultaneously brings interest back into this world and reflects how we, as a society, have kind of moved on from dinosaurs. This was actually great for Koepp and Edwards to work in conjunction in sprinkling in moments of amazement when the dinosaurs were on screen. It harkened back to the days of the '93 film, which tapped into that nostalgic feeling that we have all grown accustomed to. Yet, Koepp dug a bit deeper to give the movie its entertaining spin. Jurassic World: Rebirth draws on concepts from the Michael Crichton novel, The Lost World , and injects some horror and more intense scenes. The idea of mutated dinosaurs and the high threat level in the movie is something that kept it entertaining for the most part. Edwards has a history of working in monster films, and his talent was the perfect addition to the movie. There were several scenes in Jurassic World: Rebirth where I held my breath due to the extreme peril some of the characters faced. It allowed the movie's action to escalate in multiple settings and locations where the characters found themselves. Additionally, the character work is both a positive and a negative aspect of Jurassic World: Rebirth . Johansson excels with the material and portrays her character in a way that is reminiscent of her portrayal of Natasha Romanoff, albeit in a more enjoyable manner. Johansson came across as a tour guide on a wild jungle ride, which had fundamental elements of danger. Bailey's character felt like a cross between Alan Grant and Ian Malcom. There were moments where Bailey showed an authentic love and passion for dinosaurs, like Grant, while playing up the realistic and no-nonsense characteristics of Malcolm. Another positive aspect of the acting came from Mahershala Ali, who played Duncan Kincaid. He and the family caught in the middle of this excursion were basically the heart of the movie. Luna Blaise, David Iacono, Manuel Garcia-Rulfo, Audrina Miranda, along with Ali, carried most of the emotional beats of the movie, giving the film that much-needed human connection. Although it did work when needed, it felt forced at times. Jurassic World: Rebirth stumbled during the first Act because the movie required me to connect with its characters too soon. Some of the emotional beats at the beginning and to some extent in the middle of the movie felt forced, as if they were demanding a reaction from me. There's a particular moment in Jurassic World: Rebirth where Johansson and Ali are reunited after being separated for years. The two were giving these heartfelt moments that might have looked good on paper, but ended up falling flat because they were too vague, as if setting up something that was never truly paid off. Lastly, there was a level of predictability in parts of the movie. Several characters were either not properly introduced or their presence was given short shrift. That action pretty much telegraphed who was going to die. Krebs is a character who might as well have been twirling his mustache as he grips the knife behind his back tightly. Philippine Velge and Bechir Sylvain barely have names for their characters and might as well have been referred to as Person 1 and Person 2. The movie tries to make their fates impactful, but I didn't feel anything. Jurassic World: Rebirth feels like a theme park ride for most of the movie, and that works for the B-level story. The movie might have thrived as a direct sequel to '93's Jurassic Park , and it works on some level in today's cinema world. The large, deadly dinosaur depicted in the 3rd Act has a unique appearance that lends a horror monster feel to the movie. The franchise's new direction can breathe new life into this series and is sure to be another hit for moviegoers. It's popcorn cinema for audiences, and that's okay. Grade: C
Yahoo
an hour ago
- Yahoo
FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, is pleased to invite investors to a webinar on July 10, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature FibroBiologics' Founder and Chief Executive Officer, Pete O'Heeron, who will discuss FibroBiologics' fibroblast-based cell therapy platform aimed at treating chronic, inflammatory, and degenerative conditions. Unlike traditional stem cell therapies, FibroBiologics' allogeneic fibroblast approach can potentially deliver scalable, off-the-shelf solutions that harness the regenerative and immunomodulatory power of fibroblasts—cells that are abundant, immune-privileged, and cost-efficient to manufacture. Attendees will gain insight into FibroBiologics' robust pipeline led by CYWC628 for diabetic foot ulcers and supported by additional candidates targeting multi-billion-dollar markets such as degenerative disc disease and multiple sclerosis, strong intellectual property portfolio, and anticipated upcoming clinical milestones. A live question and answer session will follow the presentation. The recording of the presentation and Q&A will be available under the investor section of the FibroBiologics website after the event. To register for the free webinar, please visit: Questions can be pre-submitted to FBLG@ or online during the live event. Cautionary Statement Regarding Forward-Looking StatementsThis communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the anticipated timing of the initiation of and results from, FibroBiologics' current and future preclinical studies, clinical trials and research and development programs, potential clinical benefits of fibroblasts and fibroblast-derived materials, potential indications for FBLG's programs, and estimates of market size. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologicsBased in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347)


Medscape
an hour ago
- Medscape
Will Mifepristone Prove a CATALYST for Change?
Expanding evidence for the impact of hypercortisolism in patients with difficult-to-control type 2 diabetes (T2D) and key insights from the CATALYST study were discussed during the final symposium at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, which I was fortunate to attend. I must be honest, the role of hypercortisolism in T2D was not hitherto on my radar. Whilst the phrase is somewhat of a cliche these days, the CATALYST trial is practice-changing for me. I'm sure we can all immediately recall patients with suboptimally managed T2D despite their positive lifestyle choices and adherence to multiple medications. We should consider whether underlying hypercortisolism is driving these patients' hyperglycemia. In the opening session of the ADA symposium, Ralph DeFronzo, MD, chief of the Diabetes Division at the University of Texas Health Science Center in San Antonio, Texas, reminded us that in T2D — which is a heterogeneous disorder — hypercortisolism plays an important role and contributes to refractory disease. In fact, DeFronzo suggested that his 'ominous octet' of core pathophysiological defects in T2D should be expanded to the 'noxious nine' to include hypercortisolism. DeFronzo made an analogy with resistant hypertension and hyperaldosteronism. Hyperaldosteronism is an etiological factor in 10%-30% of patients with resistant hypertension, and around one-third of these patients have a solitary adrenal adenoma. Yet we do not routinely screen for hyperaldosteronism in resistant hypertension. But we do commonly prescribe mineralocorticoid (primarily aldosterone) receptor antagonists such as spironolactone for these patients. This approach has proven to be an effective strategy for resistant hypertension, as demonstrated in trials such PATHWAY-2. DeFronzo also reminded us that many patients with hypercortisolism do not present with the classic phenotypic features of Cushing syndrome (ie, moon face, buffalo hump, etc). Instead, most patients with hypercortisolism present with the following 'big 4': Difficult-to-control T2D Difficult-to-control hypertension Visceral or centripetal obesity Osteoporosis or fractures. Again, I am sure we can all recall such patients. So, how does hypercortisolism cause hyperglycemia? Hypercortisolism reduces insulin secretion, increases glucagon secretion, and, interestingly, increases GLP-1 resistance, which generally results in severe insulin resistance. Hypercortisolism is a recognized contributor to T2D, metabolic syndrome, and cardiometabolic risk. The CATALYST trial sought to explore the prevalence of hypercortisolism in difficult-to-control T2D and whether treatment with mifepristone (a competitive glucocorticoid receptor antagonist) improved glycemia in patients with difficult-to-control T2D. The FDA has already approved mifepristone for the treatment of hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing syndrome who have T2D or glucose intolerance. The CATALYST trial's prevalence phase recruited 1057 patients with difficult-to-control T2D (mean HbA1c, 8.8%). Eligible participants were taking multiple glucose-lowering therapies or antihypertensive therapies or had microvascular and macrovascular complications of diabetes. Nearly a quarter of participants had hypercortisolism by overnight 1 mg dexamethasone suppression test with a cortisol cutoff of 50 nmol/L. Around one-third of individuals had an adrenal imaging abnormality. Notably, about 27% of CATALYST participants were taking three or more antihypertensive agents, and the prevalence of hypercortisolism among these patients was about 38%. Moreover, patients with hypercortisolism had more cardiovascular disease (eg, coronary artery disease, atrial fibrillation, and heart failure) and higher overall medication burden. The CATALYST trial's treatment phase investigated 136 patients with difficult-to-control T2D and hypercortisolism. Ninety-one participants were randomly assigned to receive mifepristone, and 45 participants were randomly assigned to receive placebo. The primary endpoint was change in HbA1c at 24 weeks. Secondary endpoints included changes in glucose-lowering medications, changes in hypercortisolism-related comorbidities, and improvements in cardiometabolic risk factors such as waist circumference, blood pressure, and lipid profile. Mifepristone was associated with a 1.47% reduction in HbA1c, compared with a 0.15% reduction with placebo, at 24 weeks. Differences in HbA1c were observed even after 12 weeks. Importantly, there was no difference in effect in patients with or without adrenal abnormalities. Glycemic improvements were accompanied by clinically meaningful reductions in glucose-lowering medications, weight (mean reduction, 4.4 kg), BMI (mean reduction, 1.47), and waist circumference (mean reduction, 5.2 cm). Mean blood pressure in participants taking mifepristone remained at or near the recommended target (< 130/80 mm Hg), but a mean increase of 8 mm Hg in systolic blood pressure was observed in the mifepristone group. The placebo group, however, had a reduction of 2 mm Hg. Reassuringly, in patients on mifepristone with baseline systolic blood pressure ≥ 130 mm Hg, no increases in blood pressure were observed. There were only small numerical changes in lipid profile with mifepristone. With regard to mifepristone's safety profile, 42 patients (46%) discontinued the treatment, compared with eight patients (18%) receiving placebo. Adverse events with mifepristone were mostly mild to moderate and consistent with the drug's known safety profile; no new safety signals were identified. Adverse events included hypokalemia and fatigue, nausea, vomiting, headache, and dizziness consistent with glucocorticoid withdrawal. Three participants on mifepristone experienced euglycemic ketoacidosis, and all three were receiving SGLT2 inhibitors. In conclusion, the CATALYST trial is the next evolution in personalized diabetes care. We should consider screening for hypercortisolism in patients with difficult-to-control T2D. The overnight dexamethasone suppression test can be conducted in primary care, but I am mindful of the considerable pressures we currently face in the community. Patients should take 1 mg of dexamethasone around 11 pm or midnight and have their serum cortisol levels checked at around 8 or 9 am. A morning cortisol level of < 50 nmol/L excludes hypercortisolism. We should be aware of common causes of false positive results, including use of the combined oral contraceptive pill; use of exogenous steroids; severe psychiatric, medical, or surgical illness; night shift work; excess alcohol intake; severe untreated sleep apnea; and hemodialysis or end-stage renal disease. CT scans should also be performed to establish whether the disease could be surgically remediable. Access to CT is challenging, given the current climate in primary care, but improvements in HbA1c were seen irrespective of adrenal abnormalities. Treatment with mifepristone must be individualized to maintain the drug's risk-benefit ratio; the compelling benefits in HbA1c and overall cardiometabolic risk reduction must be balanced against the side effects of hypokalemia and glucocorticoid withdrawal. Counseling about sick day guidance remains pivotal for patients on SGLT2 inhibitors, and blood pressure will also need to be monitored regularly. To paraphrase Paracelsus (1493-1541), the Swiss physician and founder of toxicology, 'No drug is without poison; the dosage makes it a poison or a remedy.'